tesamorelin / ipamorelin + Blend Tesamorelin + Ipamorelin (10/3 MG)

It is FDA-approved for reducing excess visceral fat in HIV-positive patients with lipodystrophy

For further optimization, the central gene fragment of PapRS#0, flanked by the two Bsa I restriction sites, was subjected to error-prone PCR using the GeneMorph II random mutagenesis kit (Agilent), adjusting a mutagenesis frequency of 4 nucleotide exchanges

This is a research blend of two distinct and mechanistically complementary growth hormone secretagogues, supplied together to enable dual-pathway GH axis research in a single formulation

Care is provided only after clinical review and informed consent, including assessment of history, goals, risks, and potential interactions

This work was supported by Project funded by China Postdoctoral Science Foundation (2022M713650)

This short-acting pulsatile effect makes it suitable for once-daily administration to support physiological GH patterns